Frequency of Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma: Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma

Muhammad Nabeel Shafqat; Najam us Sehar Saeed; Salman Javed; Muhammad Adil Chouhdary; Ghania Shafqat; Muhammad Asad Aftab

doi:10.54393/pjhs.v3i05.219

Authors

Muhammad Nabeel Shafqat Department of Gastroenterology, Gujranwala Medical College/DHQ Hospital Gujranwala, Pakistan
Najam us Sehar Saeed Gujranwala Medical College, DHQ Hospital, Gujranwala, Pakistan
Salman Javed Services Institute of Medical Sciences, Services Hospital, Lahore, Pakistan
Muhammad Adil Chouhdary Department of Gastroenterology, Gujranwala Medical College/DHQ Hospital Gujranwala, Pakistan
Ghania Shafqat Shalamar Institute of Health Sciences, Lahore, Pakistan
Muhammad Asad Aftab Punjab Institute of Cardiology, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v3i05.219

Keywords:

Hepatocellular carcinoma, Portal vein thrombosis, chronic viral hepatitis

Abstract

The hepatocellular carcinoma (HCC) is a frequent complication of liver. Portal vein thrombosis is common in HCC patients and associated with poor prognosis. But evidence lacks for local population. Objective: To assess the frequency of portal vein thrombosis in diagnosed patients of hepatocellular carcinoma presenting at DHQ hospital, Gujranwala. Methods: After permission from the ethical committee, this cross sectional study was done at the Department of Gastroenterology, DHQ hospital, Gujranwala from 19-03-2021 to 19-09-2021. Total 125 patients were selected from OPD. Informed consent was taken. All patients underwent Doppler ultrasound to diagnose the portal vein thrombosis. All data was analyzed in SPSS 22. Results: Total of 125 patients, 16.8 %( n=21) were in age group of 20-40 years and 83.2 %/(n=104) were in age group of 41-60 years. Mean age was 45.52+45.05 years. Distribution of size of hepatocellular carcinoma was 4.03+0.906 cm. There were 72.0 %( n=90) male whereas 28.0% (n=35) were females. According to the type of hepatocellular carcinoma, 64.8% (n=81) had naive and 35.2% (n=44) recurrent hepatocellular carcinoma. Total of 125 patients, 64.0% (n=80) had single and 36.0% (n=45) had multiple hepatocellular carcinoma. Frequency of portal vein thrombosis was 29.6% (n=37) in patients with hepatocellular carcinoma. Conclusions: We concluded that portal vein thrombosis is common in patients with HCC. An early diagnosis of Portal vein thrombosis along with the evaluation of the volume of portal vein thrombosis on CT and an early intervention is necessary.

References

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. 2010 Dec; 127(12):2893-917. doi: 10.1002/ijc.25516.

O'Connor S, Ward JW, Watson M, Momin B, Richardson LC. Hepatocellular Carcinoma-United States, 2001-2006. Morbidity and Mortality Weekly Report. 2010; 59(17):517-20.

Crissien AM and Frenette C. Current management of hepatocellular carcinoma. Gastroenterology & hepatology. 2014 Mar;10(3):153.

Mittal S and El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. Journal of clinical gastroenterology. 2013 Jul; 47 Suppl(0):S2-6. doi: 10.1097/MCG.0b013e3182872f29.

Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, et al. Jr. Hepatocellular carcinoma: a review. Journal of hepatocellular carcinoma. 2016 Oct; 3:41-53. doi: 10.2147/JHC.S61146.

Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Annals of gastroenterological surgery. 2018 Jun; 31(3):315-329. doi: 10.20524/aog.2018.0245.

Manzano-Robleda Mdel C, Barranco-Fragoso B, Uribe M, Méndez-Sánchez N. Portal vein thrombosis: what is new? Annals of Hepatology. 2015 Feb;14(1):20-7.

Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Annals of surgery. 2001 Mar; 233(3):379-84. doi: 10.1097/00000658-200103000-00012.

Zhou Q, Wang Y, Zhou X, Peng B, Yang J, Liang L, et al. Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi. Asian Pacific journal of cancer prevention. 2011 Jan;12(11):2847-50.

Piscaglia F, Gianstefani A, Ravaioli M, Golfieri R, Cappelli A, Giampalma E, et al. Bologna Liver Transplant Group. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transplantation. 2010 May; 16(5):658-67. doi: 10.1002/lt.22044.

Alam S and Pervez R. Validity of colour doppler sonography for evaluation of portal venous system in hepatocellular carcinoma. Journal of the Pakistan Medical Association. 2013 Mar; 63(3):365-8.

Gîrleanu I, Trifan A, Stanciu C, Sfarti C. Portal vein thrombosis in cirrhotic patients - it is always the small pieces that make the big picture. World Journal of Gastroenterology. 2018 Oct; 24(39):4419-4427. doi: 10.3748/wjg. v24.i39.4419.

Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World Journal of Gastroenterology.2019 Aug; 25(31):4360-4382. doi: 10.3748/wjg. v25.i31.4360.

Ashmawy MM, Mahmoud A, El-Masry MA, Abdelaal AA. Risk factors of malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Journal of Current Medical Research and Practice. 2019 May; 4(2):203.

Connolly GC, Chen R, Hyrien O, Mantry P, Bozorgzadeh A, Abt P, et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thrombosis research. 2008; 122(3):299-306. doi: 10.1016/j.thromres.2007.10.009.

Okuda K, Ohnishi K, Kimura K, Matsutani S, Sumida M, Goto N, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology. 1985 Aug; 89(2):279-86. doi: 10.1016/0016-5085(85)90327-0.

Valla DC and Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. Journal of hepatology. 2000 May; 32(5):865-71. doi: 10.1016/s0168-8278(00)80259-7.

Ogren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World Journal of Gastroenterology. 2006 Apr; 12(13):2115-9. doi: 10.3748/wjg. v12.i13.2115.

Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. American journal of gastroenterology supplements. 2006 Jul; 101(7):1524-8; quiz 1680. doi: 10.1111/j.1572-0241.2006.00588. x.

Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation in Liver Disease Group. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006 Oct; 44(4):1039-46. doi: 10.1002/hep.21303.

Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, et al. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One. 2021 May; 16(5):e0249426. doi: 10.1371/journal.pone.0249426.